-
Mashup Score: 1
This Viewpoint discusses a current Supreme Court lawsuit, Amgen v Sanofi, involving Amgen’s broad patents on PCSK9 that could effectively prevent other manufacturers from producing similar or even clinically superior antibodies, with important negative consequences for patients.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2LDL lowering effect of PCSK9 inhibition is reduced in women - 1 year(s) ago
AbstractAims. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of plasma low-density lipoprotein cholesterol (LDL-C) concentration, and
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
#LDL lowering effect of #PCSK9i inhibition is reduced in #women. Interesting data to compare with #RCT https://t.co/YDBTzZ2N5H
-
-
Mashup Score: 13
AbstractAims. Long-term, placebo-controlled cholesterol-lowering trials have demonstrated legacy effects (clinical benefits that persist or emerge after trial e
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Few events, p=0.047 but data which reinforce that very low #LDL after #ACS is safe and associated with further reduction of #MACE #LLT #PCSK9i https://t.co/580KC9AFTG
-
-
Mashup Score: 1Hotlines ESC avec Dr Pierre Sabouret - 1 year(s) ago
Le Dr Pierre Sabouret me présente ses coups de coeur de l’ESC 2022
Source: YouTubeCategories: Cardiologists, Latest HeadlinesTweet-
ESC summary with Pierre Sabouret. #AntiXIa #LLT #TimeExposure #PCSK9i https://t.co/S92jICKYPI via @YouTube
-
-
Mashup Score: 1PCSK9 promotes arterial medial calcification - 1 year(s) ago
A complex interplay among chronic kidney disease (CKD), lipid metabolism and aortic calcification has been recognized. Here we investigated the influence of kidney function on PCSK9 levels and its potential direct action on smooth muscle cells (SMCs) calcification.
Source: AtherosclerosisCategories: Cardiologists, Latest HeadlinesTweet-
#PCSK9i : PCSK9 promotes arterial medial calcification https://t.co/TI85CcCMii with @mariagiovannalupo @MassiRuscica et al ++
-
-
Mashup Score: 2
In patients with HeFH, no unexpected long-term safety concerns were observed with alirocumab compared with previously published data; durability of LDL-C-lowering over 3 years (including 1.5 years of parent trials) was demonstrated.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
Kind reminder of the long term #safety of #Alirocumab #PCSK9i https://t.co/6047OjMpDY
-
-
Mashup Score: 2
AbstractAims. To obtain safety and efficacy data of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in a real-life setting in high cardio
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
More data from D.Gaudet and @maciejbanach among the authors. Both will be present at #EASCongress2023 #Alirocumab #PCSK9i https://t.co/b3AxLKMUyR
-
-
Mashup Score: 1
Purpose During the alirocumab open-label extension study ODYSSEY OLE (open-label extension; NCT01954394), physicians could adjust alirocumab dosing for enrolled patients, who were diagnosed with heterozygous familial hypercholesterolemia (HeFH) and who had completed previous phase III clinical trials with alirocumab. This post hoc analysis evaluated the differences in physician–patient dosing…
Source: SpringerLinkCategories: Cardiologists, Latest HeadlinesTweet-
Perception of the severity of #HeFH : big disparities. #Alirocumab #PCSK9i https://t.co/DXDHVNtXmD
-
-
Mashup Score: 1
Atherosclerotic cardiovascular disease is a systemic condition involving several vascular districts. The most involved vascular bed, beyond the coronary district, is represented by the peripheral arteries, whose involvement can give rise to cerebrovascular or peripheral events. PCSK9 inhibitors (PCS …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
https://t.co/NUEeX7jeEE #PCSK9i
-
-
Mashup Score: 6Les dernières données sur les dyslipidémies - 1 year(s) ago
Les bénéfices sur les événements ischémiques augmentent au cours du temps car le temps d’exposition aux traitements est fondamental avec une réduction de la mortalité cardiovasculaire lors du suivi prolongé des patients. Les études avec les iPCSK9 qui sont des anticorps monoclonaux 100 % humanisés ont confirmé l’excellente tolérance des taux très bas de LDL-C (moyenne des LDL-C autour de 30…
Source: Cardiologie PratiqueCategories: Cardiologists, Latest HeadlinesTweet-
Last data on dyslipidemia at @CNCFCardio congress https://t.co/FlP2GjPPoh #LLT #lipids #LDL #PCSK9i #inclisiran
-
Broad Patent Claims and Supreme Court in Amgen vs Sanofi | Law and Medicine. #PCSK9i. A key issue for #Research and new drugs. https://t.co/CZCVov8CZ4